Document
type: Class

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis
most specific type: Academic Article
type: Academic Article
type: Document
type: Entity
language: Inglese
type: Thing
type: Generically Dependent Continuant
type: Information Content Entity
type: Continuant
related by: 5478125
type: Article

Academic Article
type: Class

Continuant
type: Class

Entity
type: Class

5478125
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis

individual
rights: termsOfUse
date: 2026-08-24T02:36:02
publisher: Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis
type: Document
label: RDF description of Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis - http://irises.unisr.it/resource/item/98532

Generically Dependent Continuant
type: Class

Article
type: Class

Inglese
type: Language

Information Content Entity
type: Class